抗血管内皮生长因子药物治疗1型早产儿视网膜病变的初次治疗:美国眼科学会报告
该报告系统回顾了抗血管内皮生长因子(VEGF)药物与激光光凝治疗早产儿视网膜病变(ROP)的安全性和有效性证据,共纳入13篇文献,其中6篇为II级证据(5项随机临床试验),7篇为III级证据(比较性病例系列)。结论认为玻璃体腔注射抗VEGF药物在促使急性ROP消退方面与激光光凝同样有效,但复发率更高且需更长期 vigilant 随访,全身VEGF抑制对发育中器官系统的影响尚不明确。
要点
- II级和III级证据表明玻璃体腔抗VEGF治疗使急性ROP消退的效果与激光光凝相当。
- 部分病例(如I区病变或侵袭性后部ROP)抗VEGF药物治疗具有明确眼部优势。
- 抗VEGF治疗后ROP复发率更高,且视网膜血管化常不完全,需警惕并延长随访。
核心结论
- 当前II级和III级证据表明玻璃体腔抗VEGF治疗使急性ROP消退的效果与激光光凝相当。
- 对于某些病例(如I区病变或侵袭性后部ROP),抗VEGF药物治疗具有明确的眼部优势,但缺点是ROP复发率更高,且因视网膜血管化通常不完全而需要警惕和延长随访。
- 玻璃体腔注射后1天内可在血清中检测到贝伐珠单抗,血清VEGF水平被抑制至少8至12周。
- 降低全身VEGF水平对早产儿发育中器官系统的影响尚不清楚,抗VEGF用于ROP治疗后的潜在全身和神经发育影响的长期数据有限。
- 抗VEGF药物应审慎使用,并需了解已知和未知或潜在的副作用。
研究设计与样本
- 文献检索于2016年9月6日最后一次进行,检索PubMed和Cochrane图书馆数据库,无日期限制,仅限于英文发表的文章。
- 检索共获得311条引用,其中37篇被认为具有临床相关性并进行全文审查,最终13篇被选入本评估。
- 13篇文献中,6篇关于5项随机临床试验的文章提供II级证据,支持抗VEGF药物作为单药治疗或联合激光治疗使用。
- 7篇为比较性病例系列,提供III级证据。
- 专家方法学家根据证据水平对所选文章进行评级。
主要发现
- 6篇II级证据文章的主要结局包括ROP复发和需要再次治疗(3篇)、视网膜结构(2篇)和屈光结局(1篇)。
- 7篇III级证据比较性病例系列的主要结局包括抗VEGF治疗对外周视网膜血管发育的影响(1篇)、屈光结局(1篇),或结构和屈光或视觉结局(5篇)。
- 玻璃体腔注射后1天内可在血清中检测到贝伐珠单抗,血清VEGF水平被抑制至少8至12周。
- 降低全身VEGF水平对早产儿发育中器官系统的影响尚不清楚,抗VEGF用于ROP治疗后的潜在全身和神经发育影响的长期数据有限。
临床怎么用
- 抗VEGF药物应审慎使用,并需了解已知和未知或潜在的副作用。
- 对于某些病例(如I区病变或侵袭性后部ROP),抗VEGF药物治疗具有明确的眼部优势。
- 抗VEGF治疗后ROP复发率更高,且视网膜血管化通常不完全,需要警惕和延长随访。
局限性
- 降低全身VEGF水平对早产儿发育中器官系统的影响尚不清楚。
- 抗VEGF用于ROP治疗后的潜在全身和神经发育影响的长期数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To review the available evidence on the ocular safety and efficacy of anti-vascular endothelial growth factor (VEGF) agents for the treatment of retinopathy of prematurity (ROP) compared with laser photocoagulation therapy. METHODS: A literature search of the PubMed and Cochrane Library databases was conducted last on September 6, 2016, with no date restrictions and limited to articles published in English. This search yielded 311 citations, of which 37 were deemed clinically relevant for full-text review. Thirteen of these were selected for inclusion in this assessment. The panel methodologist assigned ratings to the selected articles according to the level of evidence. RESULTS: Of the 13 citations, 6 articles on 5 randomized clinical trials provided level II evidence supporting the use of anti-VEGF agents, either as monotherapy or in combination with laser therapy. The primary outcome for these articles included recurrence of ROP and the need for retreatment (3 articles), retinal structure (2 articles), and refractive outcome (1 article). Seven articles were comparative case series that provided level III evidence. The primary outcomes included the effects of anti-VEGF treatment on development of peripheral retinal vessels (1 article), refractive outcomes (1 article), or both structural and refractive or visual outcomes (5 articles). CONCLUSIONS: Current level II and III evidence indicates that intravitreal anti-VEGF therapy is as effective as laser photocoagulation for achieving regression of acute ROP. Although there are distinct ocular advantages to anti-VEGF pharmacotherapy for some cases (such as eyes with zone I disease or aggressive posterior ROP), the disadvantages are that the ROP recurrence rate is higher, and vigilant and extended follow-up is needed because retinal vascularization is usually incomplete. After intravitreal injection, bevacizumab can be detected in serum within 1 day, and serum VEGF levels are suppressed for at least 8 to 12 weeks. The effects of lowering systemic VEGF levels on the developing organ systems of premature infants are unknown, and there are limited long-term data on potential systemic and neurodevelopmental effects after anti-VEGF use for ROP treatment. Anti-VEGF agents should be used judiciously and with awareness of the known and unknown or potential side effects.
引用
- VanderVeen DK, Melia M, Yang MB, et al. Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity: A Report by the American Academy of Ophthalmology. Ophthalmology. 2017. PMID: 28341474. doi:10.1016/j.ophtha.2016.12.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。